The RED-C Studies were two clinical trials evaluating an investigational drug given twice daily, to see if it would help delay the first episode of overt hepatic encephalopathy requiring hospitalization in patients with liver cirrhosis. The Sponsor’s goal was to accelerate recruitment for this program using a suite of study materials developed by the Stark / Raving Health team. Our approach focused on establishing a unique study brand identity combined with recruitment and educational materials that engaged and empowered patients to consider participation.
Case Studies
Dahlias Clinical Trial
Primary Sjogren’s Syndrome
Emerald Clinical Trial
Macrophage Activation Syndrome
SunRISe Clinical Trials
Muscle-Invasive Bladder Cancer
SGNS40-002 Clinical Trial
Melanoma and Non-small Cell Lung Cancer
Nanoray-312 Clinical Trial
Locally Advanced Head and Neck Cancer
Affordable Insulin Project
Insulin Dependent Diabetes
LevoCept Clinical Trial
Reversible Intrauterine System
Yellowstone Clinical Trials
Crohn’s Disease
Zuma-12 Clinical Trial
Large B-Cell Lymphoma
Mountaineer Clinical Trial
HER2+ Gastroesophageal Cancer
Skylight Clinical Trials
Vasomotor Symptoms
Phearless Clinical Trial
Phenylketonuria (PKU)
PREVENT-HD Clinical Trial
COVID-19
TRANSFORM Clinical Trial
Primary Biliary Cholangitis (PBC)
ENliven Clinical Trial
Nonalcoholic Steatohepatitis (NASH)
Triumph Clinical Trial
ADHD in Adolescents
ECHELON-3 Clinical Trial
Large B-Cell Lymphoma
Forte and Ardent Clinical Trials